STIMTAVI : Evolution of Atrioventricular Conduction Disorders After TAVI
STIMTAVI
STIMulation Cardiaque et TAVI : évolution Des Troubles Conductifs Atrio-ventriculaires après TAVI
1 other identifier
observational
275
0 countries
N/A
Brief Summary
The investigators propose to carry out an observational study of patients implanted with a pacemaker using AAI SafeR® mode after a TAVI procedure. This study aims to define the persistence or not of high-grade AVB beyond seven days after the procedure, based on the analysis of PM memories, and define definitive cardiac pacing indications after TAVI procedure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2015
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2015
CompletedFirst Submitted
Initial submission to the registry
October 20, 2017
CompletedFirst Posted
Study publicly available on registry
November 9, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 19, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
April 19, 2018
CompletedNovember 9, 2017
November 1, 2017
2.2 years
October 20, 2017
November 7, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To look for one or several high level A-V block episodes beyond seven days after a TAVI procedure, by the analysis of the EKG and of the pacemaker memories during the follow-up visits
High level A-V Block in patients after TAVI procedure is defined: * Either by the analysis of the pacemaker memories during the follow-up visits showing the switches from AAI Safe-R to DDD mode after one or more of these three reasons: * a succession of at least 2 consecutive blocked P waves * more than 3 blocked P waves among 12 consecutive cycles * ventricular pause for over 2 seconds with at least one blocked P wave * Either by the presence of a high level AVB on the EKG during the follow-up visit (pacemaker temporally set to DDI 30 bpm mode) We classify as transitional AVB (D7 persistent, non-persistent beyond 1 month), and permanent AVB (persistent beyond 1 month).
Until the completion of the study (first follow-up visit 1 to 3 months after TAVI, last follow-up visit 1 year after TAVI)
Secondary Outcomes (1)
To study the influence of certain predefined factors on the risk of high-level A-V block after a TAVI procedure.
An average of 8 days (from the day before the TAVI procedure to 7 days after TAVI)
Eligibility Criteria
275 patients over 18 years who underwent implantation of a TAVI and that were implanted during the hospitalization with a dual chamber pacemaker Sorin®, set in AAI SafeR ® or AAI SafeR-R® mode.
You may qualify if:
- All patients over 18 years who underwent implantation of a TAVI and that were implanted during the hospitalization with a dual chamber pacemaker Sorin®, set in AAI SafeR ® or AAI SafeR-R® mode.
You may not qualify if:
- Patients with life expectancy at hospital discharge estimated as less than 1 year
- TAVI procedure failure
- Patients refusing to be involved in the study
- Patients implanted with a PM of a brand different than Sorin® during the hospital phase or implanted Sorin® PM but not set in a AAI or AAI SafeR SafeR-R mode
- Patients with PM implant before TAVI
- Permanent AF at the implantation time
- Patients with Single or Triple chamber PM
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Association de Recherche en Cardiologie des Alpeslead
- LivaNovacollaborator
Related Publications (1)
Irles D, Salerno F, Cassagneau R, Eschalier R, Maupain C, Dupuis JM, Mansourati J, Guedon L, Marijon E, Frey P; Other members of the STIMulation cardiaque post-TAVI (STIM-TAVI) study. Evolution of high-grade atrioventricular conduction disorders after transcatheter aortic valve implantation in patients who underwent implantation of a pacemaker with specific mode-that minimizes ventricular pacing-activated. J Cardiovasc Electrophysiol. 2021 May;32(5):1376-1384. doi: 10.1111/jce.14970. Epub 2021 Mar 4.
PMID: 33625762DERIVED
Study Officials
- STUDY DIRECTOR
Didier IRLES, Dr
Association de Recherche en Cardiologie des Alpes
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 20, 2017
First Posted
November 9, 2017
Study Start
November 1, 2015
Primary Completion
January 19, 2018
Study Completion
April 19, 2018
Last Updated
November 9, 2017
Record last verified: 2017-11